A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Inclusion Criteria
Exclusion Criteria
Caba, B C1425FVH, Argentina
Ciudad Autónoma Buenos Aires, C 1181, Argentina
Shenzhen Shi, Guangdong 518020, China
Yichang Shi, HE 443099, China
Freiburg I. Breisgau, Baden-Wurttemberg 79106, Germany
Pylaia-Chortiatis, B 570 10, Greece
Koriyama-shi, Fukushima 9630197, Japan
Naka-gun, Gunma 3191113, Japan
Himeji-Shi, Hyōgo 670-8520, Japan
Matsusaka-shi, Mie-ken 515-8544, Japan
Ginowan-Shi, Okinawa 901-2214, Japan
Osakasayama-shi, Osaka 589-8511, Japan
Shimotsuge-shi, Tochigi 329-0498, Japan
Bunkyo-Ku, Tokyo 113-8519, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Mitaka-shi, Tokyo 181-8611, Japan
Shinjuku-Ku, Tokyo 160-0023, Japan
Iizuka-shi, 820-8505, Japan
Izumo-Shi, 693-8501, Japan
Kamogawa-Shi, 296-0041, Japan
Shinjyu-Ku, 162-8655, Japan
Tenri-Shi, 632-8552, Japan
Yoshida-Gun, 910-1193, Japan
Jongno-gu, Seoul 03080, South Korea
Yongsan-gu, Seoul 4401, South Korea
Dong-gu, Ulsan 44033, South Korea
Bucheonsi Weonmigu, 14647, South Korea
Haeundae-Gu, 48108, South Korea
Iksansi, 54538, South Korea
Suwon, Gyeonggi-do, 16499, South Korea
Douliu Shi, YUN 640, Taiwan
Pasaport, 35210, Turkey (Türkiye)